II. Mechanism

  1. Targeted to Tyrosine Kinases, interfering with EGFR, HER2-neu and VEGF
  2. Small molecules that principally act intracellularly
  3. Less specific than monoclonal antibodies

III. Pharmacokinetics

  1. Oral agents
  2. Very short half life (hours)

IV. Advantages

  1. Much less expensive than monoclonal antibodies

V. Drug Interactions

  1. Multiple related to Cytochrome P450 enzymes

VI. Agents

  1. Bortezomib (Velcade)
  2. Dasatinib (Sprycel)
  3. Erlotinib (Tarceva)
  4. Gefitinib (Iressa)
  5. Imatinib (Gleevec)
  6. Lapatinib (Tykerb)
  7. Sorafenib (Nexavar)
  8. Sunitinib (Sutent)

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window